论文部分内容阅读
作者给初治的原发性血小板增多症符合以下标准的患者,给以噻替派和瘤可宁联合化疗:①血小板数超过100万/mm~3而病因不明者;②骨髓增生活跃,巨核细胞数增多;③Ph~1染色体阴性;④白细胞碱性磷酸酶积分正常或增高;⑤红细胞数正常或血红蛋白少于13g/dL。骨活检有明显的骨髓纤维化或缺铁合并血小板增多者除外。给药方法:噻替派25mg/M~2,静注,每周1次直到血小板数降至100万/mm~3以下;在给药时同时口服瘤可宁6mg/M~2,每日1次。每周随访病人,直至血小板数降至40万/mm~3则改为每月随访1次。当血小板
The authors give initial treatment of patients with primary thrombocytosis meet the following criteria, to give thiotepa and tumor Ning combination chemotherapy: ① platelets over 1 million / mm ~ 3 and unknown etiology; ② bone marrow hyperplasia, megakaryocyte Cell number increased; Phh ~ 1 chromosome negative; ④ leukocyte alkaline phosphatase score normal or increased; ⑤ normal red blood cell or hemoglobin less than 13g / dL. Bone biopsy with significant myelofibrosis or iron deficiency combined with thrombocytosis were excluded. Method of administration: thiotepa 25mg / M ~ 2, intravenous injection once a week until the number of platelets dropped to 1 million / mm ~ 3 below; while oral administration of tumor Ning Ning 6mg / M ~ 2, daily 1 time. Weekly follow-up of patients, until the number of platelets dropped to 40 million / mm ~ 3 was changed to a monthly follow-up. When platelets